Haemonetics Corp. Announces Executive and Board Changes
Ticker: HAE · Form: 8-K · Filed: Jan 3, 2025 · CIK: 313143
| Field | Detail |
|---|---|
| Company | Haemonetics Corp (HAE) |
| Form Type | 8-K |
| Filed Date | Jan 3, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, board-change, personnel
Related Tickers: HSIC
TL;DR
Haemonetics CFO Brenda Laursen moves to Corp Dev, Brian Smith takes over as CFO. Two new directors join the board.
AI Summary
Haemonetics Corp. announced on December 27, 2024, a series of executive and board changes. Effective January 3, 2025, Brenda L. Laursen will transition from her role as Chief Financial Officer to Senior Vice President, Corporate Development. Concurrently, Brian J. Smith will assume the role of Chief Financial Officer. Additionally, the company announced the election of two new independent directors, Dr. David M. R. Johnson and Ms. Sarah E. O'Hara, to its Board of Directors, effective January 3, 2025.
Why It Matters
These changes in key financial leadership and board composition could signal strategic shifts or a focus on future growth initiatives for Haemonetics.
Risk Assessment
Risk Level: low — The filing reports routine executive and board changes without any indication of financial distress or significant operational issues.
Key Players & Entities
- Haemonetics Corp. (company) — Registrant
- Brenda L. Laursen (person) — Outgoing CFO, incoming SVP Corporate Development
- Brian J. Smith (person) — Incoming CFO
- Dr. David M. R. Johnson (person) — Newly elected independent director
- Ms. Sarah E. O'Hara (person) — Newly elected independent director
- December 27, 2024 (date) — Date of earliest event reported
- January 3, 2025 (date) — Effective date of changes
FAQ
What is Brenda L. Laursen's new role and when does it become effective?
Brenda L. Laursen will transition to Senior Vice President, Corporate Development, effective January 3, 2025.
Who is the new Chief Financial Officer of Haemonetics Corp.?
Brian J. Smith will assume the role of Chief Financial Officer.
When are the changes in executive and board positions effective?
The changes are effective January 3, 2025.
How many new independent directors were elected to the Board of Directors?
Two new independent directors, Dr. David M. R. Johnson and Ms. Sarah E. O'Hara, were elected.
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is December 27, 2024.
Filing Stats: 459 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2025-01-03 06:08:25
Filing Documents
- hae-20241227.htm (8-K) — 23KB
- 0000313143-25-000003.txt ( ) — 143KB
- hae-20241227.xsd (EX-101.SCH) — 2KB
- hae-20241227_lab.xml (EX-101.LAB) — 21KB
- hae-20241227_pre.xml (EX-101.PRE) — 12KB
- hae-20241227_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HAEMONETICS CORPORATION January 3, 2025 By: /s/ Christopher A. Simon Name: Christopher A. Simon Title: President and Chief Executive Officer